Taiwanese-developed enterovirus vaccine ships to Vietnam

Medigen's enterovirus 71 (EV71) vaccine has officially begun exporting to Vietnam, marking a significant achievement for Taiwan's indigenous vaccine development. After securing marketing approval in Vietnam in the first half of the year, the vaccine successfully completed its first international shipment following stringent quality inspections and batch release procedures.

“

The EV71 vaccine has officially shipped to Vietnam, becoming the first domestically developed novel vaccine to successfully enter the overseas market, achieving an important milestone for Taiwan's vaccines!

To ensure the highest quality, Medigen utilized specialized "actively temperature-controlled containers" equipped with precise digital temperature control and independent power systems. This meticulous approach guarantees that each vaccine dose maintains its integrity from production to arrival in Vietnam.

“

Medigen's EV71 vaccine uses the highest specification 'actively temperature-controlled containers' with precise digital temperature control and independent power systems to ensure that every dose of vaccine arriving in Vietnam maintains the same highest quality as when it left the factory.

This initial shipment is just the beginning. Medigen anticipates sending additional batches of the EV71 vaccine to Vietnam later this year. Furthermore, the company is actively pursuing drug approval in other Southeast Asian nations, positioning Taiwan-made vaccines for broader regional success and potentially becoming another source of national pride.

“

In addition to the first batch of vaccines, Medigen will have other batches of EV71 vaccines entering Vietnam this year, and other Southeast Asian countries are also continuously applying for drug approval. Taiwan-made EV71 vaccines will become another Taiwanese pride in Southeast Asia.